Perhaps The Slow-Going Over Past Year Will Be Changed By Upcoming Mediations With Two Special Masters Appointed Recently By Judge Herndon
In their Stockholders' Newsletter Financial Report as of June 30, 2014, Second Quarter of 2014 (PDF) Bayer informs at page 54 that as of July 2, 2014:
- Settlements with about 8,900 claimants for total of $1.8 billion;
- The number of pending claims with deep vein thrombosis (DVT) and/or pulmonary embolism (PE) -- the "venous clot injuries" -- is approximately 2400; and,
- There are an estimated 2,600 claims with other alleged drospirenone (DRSP) related injuries, such as arterial clots.
Significant or not, in their latest quarterly report Bayer continues to only allude to YAZ, Yasmin, Ocella, and Gianvi cases -- while still making no mention of there being any Beyaz and Safyral cases filed (which there are, in fact).
Free Case Evaluation
Strictly Confidential, No Obligation.
So where do things stand in comparison to our last article about the Bayer DRSP birth control pills litigation? From just looking below at the title and sub-title of this June 2014 item we can see that more new blood clot cases have been filed than there have been older cases settled, using Bayer's numbers.
About 2000 YAZ / Yasmin / Ocella / Gianvi Blood Clot Cases Are Still Not Settled More Than Two Years After Bayer Began Settlement Mediations
Bayer Reports That As Of April 8, 2014 Settlement Negotiations Have Resolved "approximately 8,560 claimants in the U.S. for a total amount of about US$1.74 billion"
One hopes that the August 28 Case Management Order wherein Judge David Herndon, who is presiding over the Yasmin / YAZ federal court MDL consolidation, appointed two special masters "for the purpose of mediating settlement" will serve to move this litigation toward a total resolution at a faster pace than has been the experience of this past year.